BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 23, 2020
View Archived Issues
Glial metabolism affects neural recovery
Read More
Kemp Proteins to provide assay development for first-in-class chronic SCI therapy, AXER-204
Read More
Genentech and Roche divulge new antibacterials
Read More
Gilead Sciences presents new PKC agonists
Read More
First-in-human study of IGM-8444 begins in patients with solid tumors
Read More
AbbVie and Galapagos identify CFTR mutant correctors
Read More
New potential broad-spectrum fungicides discovered
Read More
Phase I data for sotorasib in advanced solid tumors harboring the KRAS p.G12C mutation
Read More
Researchers develop mouse-adapted SARS-CoV-2 model causing age-related disease pathogenesis
Read More
Cyteir Therapeutics describes RAD51A inhibitors
Read More
REVOLUTION Medicines patents SOS1 inhibitors
Read More
P2X4R inhibition reduces proinflammatory myeloid cells, offering neuroprotection after stroke
Read More
First clinical data presented for first-in-class NOTCH inhibitor CB-103
Read More
Henlius reports phase III data on bevacizumab biosimilar HLX-04
Read More
First-in-human study evaluates AZD-8701 alone and with durvalumab in advanced solid tumors
Read More
Debio-1143 studied in phase III with chemoradiotherapy for locally advanced SCCHN
Read More
M-8891 has manageable safety profile and favorable PK in first-in-human study
Read More
ILT4 antibody MK-4830 well tolerated, shows encouraging responses in phase I study
Read More
First-in-human data presented for TLD-1
Read More
Micreos begins phase I/IIa study of endolysin XZ.700 in atopic dermatitis
Read More
Durect eyes initiation of phase IIb trial of DUR-928 in alcoholic hepatitis
Read More
Vaccinex reports topline phase II data on pepinemab in Huntington's disease
Read More
FDA accepts IND for adoptive T-cell therapy GEN-011
Read More
